Thomas Uldrick Jr. MD

Deputy Head, Global Oncology

1100 Fairview Ave NMail Stop M1-B140Seattle, WA 98109
Phone+1 206-667-7485
Fax+1 206-667-1965

Dr. Uldrick is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Uldrick's full profile Already have an account?

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2005 - 2008
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2002 - 2005
State University of New York Downstate Medical Center College of MedicineClass of 2002

The following disclaimer is related to board certifications obtained from ABMS®, denoted by the ABMS® logo.

This information is proprietary data maintained in a copyrighted database owned by the American Board of Medical Specialties®. The display and presence of ABMS Data in no way constitutes any affiliation, association with, or endorsement of any advertising, promotion, or sponsorship by ABMS and its affiliates and subsidiaries, the ABMS Member Boards, or ABMS board certified physicians and medical specialists. Copyright 2026 American Board of Medical Specialties®. All rights reserved.

The user is responsible for ensuring that the profile obtained in this directory is the profile of the physician or medical specialist being sought.

A self-designated specialty, subspecialty, or practice area neither implies nor is equivalent to ABMS board certification or the existence of specialized training by or competence of a physician or medical specialist.

Certifications & Licensure

WA State Medical License 2017 - 2028
NY State Medical License 2004 - 2021

Clinical Trials

Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer Start of enrollment: 2016 Apr 04
COMPLETED
PHASE1
Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell Lymphoma Start of enrollment: 2017 Jul 03
ACTIVE_NOT_RECRUITING
PHASE1, PHASE2
Rituximab Hyaluronidase in Combination With Chemotherapy in Treating Aggressive B-cell Lymphoma in Uganda Start of enrollment: 2019 Oct 24
Terminated
Phase 1

Publications & Presentations

PubMed

1 citations
Innate antiviral and immune functions associated with the HIV reservoir decay after anti-PD-1 therapy.
Aarthi Talla, Joao L L C Azevedo, Muhammad Bilal Latif, Ana B Enriquez, Gabriela Pacheco Sanchez
Nature Medicine. 2026-02-01
1 citations
Cytokine biomarkers and their relationship to symptoms and quality of life in people with HIV-associated Kaposi sarcoma.
Fahmida Shaik, Thomas Smith Uldrick, Mikateko Mazinu, Nomonde Gwebushe, Anisa Mosam
HIV Medicine. 2025-12-01
5 citations
Characteristics and outcomes of Kaposi sarcoma herpesvirus-associated inflammatory cytokine syndrome.
Ramya Ramaswami, Kathryn Lurain, Mark N Polizzotto, Anaida Widell, Irene Ekwede
Blood Advances. 2025-11-25

Journal Articles

Discovery of Kaposi’s Sarcoma Herpesvirus-Encoded Circular RNAs and a Human Antiviral Circular RNA
Ramya Ramaswami, Kathryn Lurain, Thomas S Uldrick, Proceedings of the National Academy of Sciences
International, Evidence-Based Consensus Treatment Guidelines for Idiopathic Multicentric Castleman Disease
Aaron Goodman, Corey Casper, Sudipto Mukherjee, Peter Voorhees, Angela Dispenzieri, David C Fajgenbaum, Razelle Kurzrock, Raj Jayanthan, Sunita Nasta, Thomas S Uldrick..., Blood

Abstracts/Posters

Natural History Study of Idiopathic Multicentric Castleman Disease Identifies Effective Treatments for a Large Proportion of Patients but Treatment-Refractory Patients...
Thomas S. Uldrick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
High Rate of Exclusion of HIV Infected Patients from Modern Lymphoma Studies: An Analysis of Current United States Therapeutic Trials
Thomas S. Uldrick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Phase I/II Study of Lenalidomide Combined with DA-EPOCH and Rituximab (DA-EPOCH-R2) in Primary Effusion Lymphoma in Patients with or without HIV
Thomas S. Uldrick, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

Phase I study of pembrolizumab in people with HIV and cancer.
2019 ASCO Annual Meeting - 6/1/2019
Pathologic Misdiagnosis in Children with Suspected Burkitt Lymphoma Associated with Early MortalityClinically Relevant Abstract
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018

Press Mentions

Cancer Immunotherapy Flushes HIV Out of HidingFebruary 9th, 2022
Cancer Drug Flushes Out Latent HIV, Exciting New Study FindsJanuary 28th, 2022
Anti-Cancer Drug Can Flush Out HIV Hiding in Cells, Study SuggestsJanuary 27th, 2022